Dopaminergic medication improves cognitive control under low cognitive demand in Parkinson's disease.

Neuropsychology

Cognitive Motor Neuroscience Group, Sobell Department of Motor Neuroscience and Movement Disorders, UCL Queen Square Institute of Neurology.

Published: July 2020

Objective: Dopamine agonists are the main pharmacological intervention for the motor symptoms of Parkinson's disease (PD). However, dopaminergic medication has been associated with disinhibitory psychopathology in some patients. The aim of this study was to test the effect of dopaminergic medication on inhibitory control in patients with PD using the paced Random Number Generation task (RNG), which requires inhibition of prepotent counting in series to produce a random sequence of numbers.

Method: Twenty-three PD patients performed RNG on and off dopaminergic medication. Cognitive load was manipulated by performing RNG at faster (1Hz) and slower (0.5 Hz) rates. For RNG, two scores (CS1 and CS2) were derived, which are considered indices of more automatic and more controlled counting, respectively.

Results: There were no main effects of medication on RNG performance. There was a significant main effect of cognitive load on CS1, with higher CS1 scores at the faster rate ( = <.01). A significant interaction effect between medication and rate (cognitive load; = .03) followed by post hoc testing, revealed that CS2 scores were higher, on medication, at the slower but not the faster rate.

Conclusions: Patients with PD displayed increased use of more controlled processing strategies on medication at the slowest rate of RNG. Therefore, while dopaminergic medication has been associated with disinhibitory psychopathology, our results suggest that dopamine therapy may enhance some forms of inhibitory cognitive control in PD, but only if there is sufficient time to engage controlled processing strategies. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

Download full-text PDF

Source
http://dx.doi.org/10.1037/neu0000629DOI Listing

Publication Analysis

Top Keywords

dopaminergic medication
16
parkinson's disease
8
cognitive load
8
rng
5
dopaminergic
4
medication improves
4
cognitive
4
improves cognitive
4
cognitive control
4
control low
4

Similar Publications

Morphine dependence or addiction is a serious global public health and social problem, and traditional treatments are very limited. Deep brain stimulation (DBS) has emerged as a new potential treatment for drug addiction. Repeated use of morphine leads to neuroadaptive and molecular changes in the addiction-related brain regions.

View Article and Find Full Text PDF

Evolutionary origins of synchronization for integrating information in neurons.

Front Cell Neurosci

January 2025

The Research Center for Brain Function and Medical Engineering, Asahikawa Medical University, Asahikawa, Japan.

The evolution of brain-expressed genes is notably slower than that of genes expressed in other tissues, a phenomenon likely due to high-level functional constraints. One such constraint might be the integration of information by neuron assemblies, enhancing environmental adaptability. This study explores the physiological mechanisms of information integration in neurons through three types of synchronization: chemical, electromagnetic, and quantum.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects.

View Article and Find Full Text PDF

The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases.

Brain Behav Immun Health

February 2025

Pediatric and Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children Medical Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS), are characterized by progressive neuronal loss and cognitive impairment (CI). The: Cysteine-X-cysteine chemokine ligand 12(CXCL12)/CXC chemokine receptor type 4 (CXCR4)/CXC chemokine receptor type 7 (CXCR7) axis has emerged as a critical molecular pathway in the development of CI in these disorders. This review explores the role of this axis in the pathogenesis of CI across these neurodegenerative diseases, synthesizing current evidence and its implications for targeted therapies.

View Article and Find Full Text PDF

Blepharospasm (BSP) is a common focal movement disorder linked to the basal ganglia and plasma catecholamines (CAs). This study aimed to analyze clinical characteristics of BSP patients and explore the relationship with plasma CAs. Clinical characteristics, clinician-rated scales, and plasma CAs were recorded, including dopamine (DA), 3-methoxytyramine (3-MT), and the 3-MT/DA ratio.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!